Nektar Therapeutics
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Howard W. Robin
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 455 Mission Bay Boulevard South San Francisco CA United States of America 94158
- IPO Date
- May 3, 1994
- CIK
- 0000906709
- Website
- nektar.com
- Similar Companies
- Business
- Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, discovers, develops and commercializes therapies that selectively modulate the immune system to treat autoimmune disorders, inflammatory conditions and cancer; its lead product candidate, rezpegaldesleukin (REZPEG), is a regulatory T cell stimulator in Phase 2b clinical development for atopic dermatitis, alopecia areata and new-onset Type 1 diabetes, with FDA Fast Track designation granted for severe-to-very-severe alopecia areata in 2025; the company's immuno-oncology pipeline features NKTR-255, an engineered IL-15 receptor agonist evaluated in ongoing trials in combination with checkpoint inhibitors, TIL therapy and CAR-T therapies for solid tumors and hematological malignancies; preclinical programs include NKTR-0165, a TNFR2 agonist antibody for multiple sclerosis, vitiligo and ulcerative colitis with a planned first-in-human study in 2026, NKTR-0166, a TNFR2 bispecific antibody for rheumatic diseases, and NKTR-422, a CSF1R agonist for inflammation resolution. Founded in 1990 and headquartered in San Francisco, California, Nektar Therapeutics operates primarily in the United States with global clinical trial activities and partnerships extending internationally; the company leverages proprietary polymer conjugate technologies and immunology expertise to enhance drug pharmacokinetics, efficacy and patient convenience across autoimmune, inflammatory and oncology segments, targeting patients with unmet needs in immune-mediated diseases. Recent developments include completion of enrollment in the REZOLVE-AA Phase 2b trial for rezpegaldesleukin in alopecia areata and REZOLVE-AD trial data presentations at EADV and ACAAI 2025 meetings demonstrating statistical significance in endpoints for atopic dermatitis; in early 2025, Nektar initiated a Phase 2 trial agreement with TrialNet for rezpegaldesleukin in Type 1 diabetes and advanced IND-enabling studies for NKTR-0165 and NKTR-0166; the company completed a $115 million public offering and ATM proceeds to bolster its balance sheet, while selling royalties on CIMZIA and MIRCERA to Royalty Pharma in a non-dilutive transaction, and Ampersand Capital Partners acquired its PEGylation reagent manufacturing business in late 2024.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
Nektar Therapeutics Q1 Earnings Call Highlights
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Nektar Therapeutics Reports First Quarter 2026 Financial Results
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR
NEKTAR DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
NKTR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & Korsinsky